Cresco Labs (CRLBF) Non-Current Assets (2019 - 2026)
Cresco Labs (CRLBF) posted Non-Current Assets of $952.2 million for Q1 2026, up 1.51% on a QoQ basis from $938.0 million in Q4 2025, and down 9.57% year-over-year from $1.1 billion in Q1 2025.
Cresco Labs (CRLBF) Non-Current Assets (2019 - 2026) Analysis & Trends
Cresco Labs' Non-Current Assets history runs 8 years deep, the most recent figure standing at $952.2 million for Q1 2026.
- Quarterly Non-Current Assets fell 9.57% year-over-year to $952.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $952.2 million (down 9.57% YoY) and the FY2025 annual result came in at $938.0 million, down 11.6% from the prior year.
- Non-Current Assets was $952.2 million for Q1 2026 at Cresco Labs, up from $938.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.4 billion in Q3 2022 and bottomed at $938.0 million in Q4 2025.
- A 5-year average of $1.1 billion and a median of $1.1 billion in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 35.08% — and 2023, when it slipped 21.78%.
- Cresco Labs' Non-Current Assets stood at $1.3 billion in 2022, then slipped by 14.1% to $1.1 billion in 2023, then dropped by 1.78% to $1.1 billion in 2024, then decreased by 11.6% to $938.0 million in 2025, then increased by 1.51% to $952.2 million in 2026.
- Business Quant data shows CRLBF's Non-Current Assets at $952.2 million in Q1 2026, $938.0 million in Q4 2025, and $1.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 952.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 952.19 Mn |
| Dec 31, 2025 | 938.03 Mn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.06 Bn |
| Sep 30, 2024 | 1.07 Bn |
| Jun 30, 2024 | 1.08 Bn |
| Mar 31, 2024 | 1.07 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.10 Bn |
| Jun 30, 2023 | 1.25 Bn |
| Mar 31, 2023 | 1.26 Bn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 1.40 Bn |
| Jun 30, 2022 | 1.39 Bn |
| Mar 31, 2022 | 1.39 Bn |
| Dec 31, 2021 | 1.36 Bn |
| Sep 30, 2021 | 1.12 Bn |
| Mar 31, 2021 | 1.03 Bn |